New Compound Improves Obesity-Related Health Complications in New Study
| Jul 27th of 2010 |
Research
Diet & Healthy Living FEATURED |
An experimental compound appears to improve metabolic abnormalities associated with obesity, according to a preliminary study led by researchers at the National Institutes of Health, A report of the study, which was conducted with obese mice, appears online today in the Journal of Clinical Investigation.
Mental Decline Thwarted in Aging Rats
| Jul 21st of 2010 |
Research
Mental Health Alzheimer's Disease FEATURED |
Scientists have discovered a compound that restores the capacity to form new memories in aging rats, likely by improving the survival of newborn neurons in the brain's memory hub. The research, funded in part by the National Institutes of Health, has turned up clues to a neuroprotective mechanism that could lead to a treatment for Alzheimer's disease.
Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells
| Jul 17th of 2010 |
Diseases
HIV/AIDS Immunology FEATURED BREAKING |
Scientists have discovered two potent human antibodies that can stop more than 90 percent of known global HIV strains from infecting human cells in the laboratory, and have demonstrated how one of these disease-fighting proteins accomplishes this feat. According to the scientists, these antibodies could be used to design improved HIV vaccines, or could be further developed to prevent or treat HIV infection. Moreover, the method used to find these antibodies could be applied to isolate therape...
Gene Associated with Carney complex, a Rare Adrenal Disorder Appears To Trigger Cell Death
| Jul 16th of 2010 |
Research
Genetics Endocrine FEATURED |
A gene implicated in Carney complex, a rare disorder of the adrenal glands, appears to function as a molecular switch to limit cell growth and division, according to a study by researchers at the National Institutes of Health and other institutions. Mice lacking functional copies of the gene in the adrenal glands developed an overgrowth of adrenal tissue and were more susceptible to tumors in the gland.
Aiming for Normal Blood Sugar Does Not Delay Risk of Some Co-morbidities in Chronic Diabetes
| Jul 2nd of 2010 |
Diseases
Diabetes Stroke FEATURED BREAKING |
In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control. These findings are from the NIH-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Although intensive treatme...
Adverse Cardiovascular Events Reported in Testosterone Trial in Older Men
| Jun 30th of 2010 |
Research
Cardiovascular FEATURED |
A clinical trial of testosterone treatment in older men, reported June 30 online in the New England Journal of Medicine, has found a higher rate of adverse cardiovascular events, such as heart attacks and elevated blood pressure, in a group of older men receiving testosterone gel compared to those receiving placebo. Due to these events, the treatment phase of the trial was stopped. The study was supported by a grant to Shalender Bhasin, M.D., at Boston Medical Center from the National Institu...
FDA Approves First Generic Effexor Extended Release Capsules to Treat Major Depressive Disorder
| Jun 29th of 2010 |
Drugs
Depression Mental Health FEATURED |
On June 28, the U.S. Food and Drug Administration approved the first generic version of
Effexor XR capsules (venlafaxine hydrochloride) to treat major depressive disorder. Venlafaxine hydrochloride extended-release capsules in 37.5 milligram, 75 milligram and 150 milligram strengths have been approved to be manufactured by TEVA Pharmaceuticals, North Wales, Pa.
The National Institutes of Health - 1965
Get the Story: CDC's Global Health Odyssey Museum
FDA Drug Info Rounds, July 2010: Long-Acting Beta-Agonists (LABAs)
Read more
